As part of our oncology clinical strategy and innovation efforts, our team engages across the healthcare ecosystem to understand where cancer care is heading and how emerging advances may influence access, affordability, and care delivery - assessing innovation through both a scientific and managed care lens. 

While many meetings focus on late‑stage data or near‑term practice changes, the Precision Medicine World Conference (PMWC) operates at the front edge of development where discovery, translational science, and early implementation intersect. PMWC offers early insight into innovations being debated well before they reach guidelines, coverage policies, or routine clinical use. 

Against this backdrop, several themes from PMWC stood out this year as particularly relevant from an oncology clinical strategy and managed care perspective

Cell Therapies: From Scientific Feasibility to Scalable Potential 

Cell therapy has long represented one of the most ambitious frontiers in oncology, with early success in hematologic malignancies tempered by scientific, operational, and economic challenges. At PMWC, however, the tone of discussion suggested a meaningful inflection point - one that extends across both liquid and solid tumors. As one speaker succinctly captured, the field has moved from asking “how can this work?” to “how big can this be?” ¹˒²

A key theme underpinning this evolution is the intentional redesign of cell therapies themselves. Several sessions highlighted efforts to engineer next‑generation CAR T‑cells that maintain therapeutic benefit at significantly lower cell doses. Reducing the number of cells required for efficacy has meaningful implications. It simplifies manufacturing, improves scalability, and potentially lowers overall costs. These advances signal a growing recognition that feasibility, cost, and operational complexity must be addressed alongside efficacy if cell therapies are to achieve broader adoption.¹˒²

For health plans, this evolution is notable. As considerations around cost, scalability, and total cost of care are increasingly being embedded earlier in development, and as confidence grows that cell therapies will meaningfully extend into solid tumors, questions around affordability and realworld integration will become increasingly central to how these therapies are evaluated and adopted. 

Phase 0 Trials: Learning Earlier to Decide Smarter 

A recurring theme throughout many PMWC sessions was the role of Phase 0 and exploratory trials, underscoring mounting frustration among U.S. researchers with existing early‑phase development constraints. Although the FDA technically allows Phase 0 studies, the regulatory complexity and startup burden often negate their intended efficiency. By contrast, China and Australia offer more streamlined mechanisms that allow investigators to study drug behavior in humans earlier - providing insight into pharmacokinetics, pharmacodynamics and toxicity signals that are difficult to assess through preclinical models alone. These environments have become increasingly attractive for early development precisely because they allow uncertainty to be addressed sooner. As several speakers emphasized, many compounds in the U.S. development pipeline stall not due to lack of promise, but due to unanswered questions around target engagement and human toxicity.³˒⁴

From a system perspective, earlier clarity could improve development efficiency, reduce latestage failures, and concentrate investment on therapies with clearer clinical potential, factors that ultimately influence downstream affordability and value. 

AI as an Enabler of Precision, Not the End Goal 

AI was a prominent theme throughout PMWC, but the most compelling discussions centered on its role in advancing biomarker discovery and improving our ability to distinguish true cancer signals from biological noise. As oncology research generates increasingly complex and high‑dimensional data, speakers repeatedly emphasized that the limiting factor is no longer data availability, but interpretation. Identifying which signals are clinically meaningful, and which are incidental, remains a central challenge in precision medicine.⁵˒⁶˒⁷

Several discussions highlighted how AI‑driven approaches are being applied to integrate multimodal data sources, moving beyond genomics alone to capture additional layers of biology. By analyzing patterns across large, complex datasets, these tools may help surface biomarkers that are more predictive, more reproducible, and ultimately more actionable. Importantly, this work is less about automation and more about refinement, using AI to sharpen biological insight and improve confidence in how biomarkers are identified and validated.⁵˒⁶˒⁷

For payers and health plans, this distinction matters. Biomarkers that are better defined and more clearly linked to clinical outcomes have the potential to support more targeted treatment strategies and clearer signals of value. As AI‑enabled discovery continues to mature, its impact may be felt less through novelty and more through improved evidence quality - helping narrow the gap between scientific promise and real‑world clinical utility. 

Looking Ahead 

PMWC continues to offer a valuable window into where oncology is headed, often years before these concepts reach routine care. For health plans, engaging early with these trends provides critical context for future coverage, value assessment, and care delivery strategies. 

Precision medicine is no longer theoretical. The work now lies in determining how innovation becomes evidence, and how evidence becomes access.